Telomere Science Library

Publications, Presentations, and Videos
about the Nobel-Prize Winning Science of Telomere Biology

Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.

Authors: Julieta J. Panero, Raquel M RM. Alves-Paiva, Alejandro A. Roisman, Barbara A BA. Santana-Lemos, Roberto P RP. Falcão, Gustavo G. Oliveira, Diego D. Martins, Carmen C. Stanganelli, Irma I. Slavutsky, Rodrigo T RT. Calado
Published: 02/06/2016, American journal of hematology


Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm with poor prognosis. Acquired telomerase reverse transcriptase gene promoter (TERTp) mutations are among the most frequent somatic non-coding mutations in cancers. In this study, we investigated the prevalence of TERTp mutations in 24 MCL and 21 other lymphoid neoplasias (oLN). Eight MCL samples (33%) carried TERTp mutations, two homozygous and six heterozygous (seven C228T and one C250T), which directly correlated with higher TERT transcription, mitochondrial DNA copy number, and IGHV mutational status in MCL neoplastic cells. TERTp mutations were not found in oLN. TERTp mutations correlated with more lymphoma proliferation and tumor burden, as suggested by the higher number of lymphoma cells circulating in peripheral blood, and tended to associate with longer MCL telomeres, especially in homozygous mutants, although not statistically significant. Telomere-biology genes were overexpressed in MCL cells in comparison to healthy lymphocytes, but were not influenced by mutation status. Our findings describe for the first time that acquired TERTp mutations are common in MCL but not in other lymphoid neoplasms. We also demonstrate that TERTp mutations associate with higher TERT mRNA expression in MCL cells in vivo and higher tumor burden, suggesting these mutations as a driver event in MCL development and progression. This article is protected by copyright. All rights reserved.

© 2016 Wiley Periodicals, Inc.
PubMed Full Text